<DOC>
	<DOC>NCT00127478</DOC>
	<brief_summary>The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.</brief_summary>
	<brief_title>A Long Term Safety Study With Atrasentan</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>Greater than or equal to 18 years, inclusive; Subject is currently active in an atrasentan clinical study OR has histologically or cytologically documented diagnosis of prostate adenocarcinoma and is considered hormone refractory; Karnofsky Performance Score greater than or equal to 60; Adequate hematologic function and liver function tests; No New York Heart Association (NYHA) class greater than or equal to 2.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
	<keyword>Adenocarcinoma of the Prostate</keyword>
</DOC>